The following table provides a summary of amounts comprising the Company’s net share of the research and development costs for POSIDUR under the agreement with Hospira (in thousands):
| Year Ended December 31, | ||||||||||||
| 2013 | 2012 | 2011 | ||||||||||
|
Research and development expenses reimbursable by Hospira |
$ | — | $ | 1,968 | $ | 7,792 | ||||||
|
Research and development expenses reimbursable by the Company |
— | — | — | |||||||||
|
|
|
|
|
|
|
|||||||
|
Net payable to Hospira |
— | — | — | |||||||||
|
|
|
|
|
|
|
|||||||
|
Net receivable from Hospira |
$ | — | $ | 1,968 | $ | 7,792 | ||||||
|
|
|
|
|
|
|
|||||||